Physician profile
Asha Gupta
NPI 1669463691
$840.72
in general payments reported to CMS, 2019-2025
12 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $56.02 · 2021: $26.86 · 2022: $40.64 · 2023: $21.48 · 2024: $273 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $265.64 | 2019-2025 | Tezspire, Symbicort |
| Glaxosmithkline, LLC. | $240.78 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $66.71 | 2019-2025 | |
| Csl Behring | $56.44 | 2019-2020 | |
| Genzyme Corporation | $46.04 | 2019 | |
| Shire North American Group INC | $37.88 | 2019 | |
| Amgen INC. | $31.36 | 2024 | Tezspire |
| Grifols USA, LLC | $22.56 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.23 | 2022 | |
| Pharming Healthcare, INC. | $18.84 | 2019 | |
| Pfizer INC. | $17.67 | 2019 | |
| Aimmune Therapeutics, INC. | $15.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.